compounded semaglutide shortage US judge upholds FDA's removal of Ozempic, Wegovy from drug list Troubling Findings in Study of

The prolonged half-life ensures that therapeutic drug concentrations remain stable between doses, allowing continuous engagement with GLP-1, GIP, and glucagon receptors throughout the dosing interval

Thyroid cancer: While GLP-1s may carry a small increased risk of medullary thyroid cancer, studies have only shown this on animals, not in humans

E., Peeters, A., Cartensen, B

Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: a Mendelian randomization and colocalization study

The FDA has issued guidance on this issue - buyers using compounded GLP-1 medications should understand they're using a product in a different regulatory category than the medications studied in the major clinical trials